title: The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
abstract: We aimed to study the effectiveness of hyperbaric oxygen therapy (HOT) (100% oxygen at 2 ATA for 70 minutes each session for 20 consecutive days) on BALB/c male mice infected with Leishmania major. Fifty-one mice were assigned to six groups. Group 1 was treated with HOT from 1 day after the inoculation. In Groups 2-5, treatment began when the cutaneous lesions appeared. Group 2 received HOT only, Group 3 received topical therapy with Leshcutan only, Groups 4 and 5 received a combination of HOT and Leshcutan for 5 and 10 days respectively, and Group 6 did not receive any treatment (control group). When comparing the control group with Group 1, treatment with HOT in Group 1 did not significantly affect the time of the appearance of the lesions. In contrast, mice treated with Leshcutan demonstrated a significant difference in lesion size and spleen dimensions as compared to the rest of the mice (p<0.001). The results show that HOT treatment has no positive effect on the course of Leishmaniasis in a BALB/c mice model infected with Leishmania major. Further studies are needed with a mouse model closer to humans and with different HOT protocols.
authors.forename: Ayelet
authors.initials: A
authors.lastname: Livneh
authors.forename: Ilan
authors.initials: I
authors.lastname: Youngster
authors.forename: Yossef
authors.initials: Y
authors.lastname: El-On
authors.forename: Matitiahu
authors.initials: M
authors.lastname: Berkovitch
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Abu-Kishk
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001558:Benzethonium / Q000031:analogs & derivatives / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006931:Hyperbaric Oxygenation; D018320:Leishmania major / Q000187:drug effects*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008807:Mice, Inbred BALB C; D010303:Paromomycin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D001558:Benzethonium; D010303:Paromomycin; C005106:methylbenzethonium chloride